Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ibuprofen + cyclobenzaprine is a combination of two small molecule drugs used together for the short-term management of acute musculoskeletal pain and muscle spasms. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase enzymes, thereby reducing prostaglandin synthesis and inflammation. Cyclobenzaprine is a centrally acting skeletal muscle relaxant structurally related to tricyclic antidepressants; it acts primarily by inhibiting serotonin and norepinephrine reuptake and blocking serotonin, adrenergic, histamine, and muscarinic acetylcholine receptors in the central nervous system. The combination may be prescribed to relieve pain associated with acute muscle injuries or strains. However, clinical studies have shown that adding cyclobenzaprine to ibuprofen does not significantly improve analgesia compared to ibuprofen alone but increases the risk of central nervous system side effects such as drowsiness and dizziness[6][7][9]. This combination should be used with caution in patients with certain comorbidities (e.g., renal or hepatic impairment), in elderly patients due to increased sensitivity to side effects, and only for short durations (typically 2–3 weeks)[1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ibuprofen + cyclobenzaprine.